Русский
SARS-CoV-2 seroprevalence among the population of the Belgorod Region during the COVID-19 epidemic
DOI: https://dx.doi.org/10.18565/epidem.2021.11.1.18-24
Popova A.Yu., Ezhlova E.B., Melnikova A.A., Oglezneva E.E., Krasnoperov A.S., Lyalina L.V., Smirnov V.S., Demin A.D., Kobrinets Zh.V., Cherskova A.Yu., Zhidkov V.A., Velitchenko D.A., Arbuzova T.V., Lomonosova V.I., Totoyan A.A.
1) Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being. Moscow, Russia; 2) Directorate for the Belgorod Region, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Belgorod, Russia; 3) Center for Hygiene and Epidemiology in the Belgorod Region, Belgorod, Russia; 4) Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Saint Petersburg, Russia
Subjects and methods. The investigation was conducted as part of Stage 1 assessing herd immunity to SARS-CoV-2 among the population of the Russian Federation, by using the unified procedure developed by the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being with the participation of the Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Participants were selected by questionnaire survey and randomization. The results of surveying 2675 people were analyzed.
Results. Community immunity in the region was 8.7% with maximum (14.5%) among children aged 1-6 years. There were no statistically significant differences between men and women in the level of seroprevalence. In COVID-19 convalescents, antibodies were detected in 23.1% of cases. In contacts with COVID-19 patients, the seroprevalence level increased by 1.6 times. In individuals who were asymptomatic and had a positive PCR test, specific antibodies were detected in 21.7% of cases. The infection was asymptomatic in 93.4% of seropositive individuals.
Conclusion. The low proportion of seroprevalence among the population suggests that there may be a risk for reactivation of COVID-19.
Literature
1. Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G. et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579(7798): 265–9. doi:10.1038/s41586-020-2008-3 2. Nicholls J., Dong X.P., Jiang G., Peiris M. SARS: clinical virology and pathogenesis. Respirology. 2003; 8(Suppl 1): S6–8. doi: 10.1046/j.1440-1843.2003.00517.x 3. Porcheddu R., Serra C., Kelvin D., Kelvin N., Rubino S. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J. Infect. Dev. Ctries. 2020; 14(2): 125–8. doi: 10.3855/jidc.12600 4. Wu D., Wu T., Liu Q., Yang Z. The SARS-CoV-2 outbreak: What we know. Int. J. Infect. Dis. 2020; 94: 44–8. doi: 10.1016/j.ijid.2020.03.004 5. Kamel Boulos M.N., Geraghty E.M. Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbreaks and epidemics. Int. J. Health Geogr. 2020; 19(1): 8. doi: 10.1186/s12942-020-00202-8 6. Liu R., Han H., Liu F., Lv Z., Wu K., Liu Y. et al. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. Clin. Chim. Acta. 2020; 505: 172–5.. doi:10.1016/j.cca.2020.03.009 7. WHO Director-General’s speech at press briefing on coronavirus infection 2019-nCoV, 11 February. https://www.who.int/ru/dg/speeches/detai l/who-directorgeneral-s-remarks-at-the-media-briefing-on-2019-ncovon-11-february-2020 8. Clemente-Suarez V.J., Hormeno-Holgado A., Jimenez M., Benitez-Agudelo J.C., Navarro-Jimenez E., Perez-Palencia N. et al. Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic. Vaccines (Basel). 2020; 8(2): 236. doi: 10.3390/vaccines8020236 9. Laxminarayan R., John T.J. Is Gradual and Controlled Approach to Herd Protection a Valid Strategy to Curb the COVID-19 Pandemic? Indian Pediatr. 2020; 57(6): 505–7. doi: 10.1007/s13312-020-1844-4 10. Kochi A.N., Tagliari A.P., Forleo G.B., Fassini G.M., Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J. Cardiovasc. Electrophysiol. 2020; 31(5): 1003–8. doi: 10.1111/jce.14479 11. Juan J., Gil M.M., Rong Z., Zhang Y., Yang H., Poon L.C. Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review. Ultrasound Obstet. Gynecol. 2020; 56(1): 15–27. doi: 10.1002/uog.22088 12. Popova A.Yu., Ezhlova E.B., Mel’nikova A.A., Bashketova N.S., Fridman R.K., Lyalina L.V., Smirnov V.S., Chkhindzheriya I.G., Grechaninova T.A., Agapov K.A., Arsent’eva N.A., Bazhenova N.A., Batsunov O.K., Danilova E.M., Zueva E.V., Komkova D.V., Kuznetsova R.N., Lyubimova N.E., Markova A.N., Khamitova I.V., Lomonosova V.I., Vetrov V.V., Milichkina A.M., Dedkov V.G., Totolyan A.A. [Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic]. Problemy osobo opasnykh infektsii 2020; (3): 124–30. (In Russ.). DOI: 10.21055/0370-1069-2020-3-124-130 13. Newcombe R.G. Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods. Statistics in Medicine 1998; 17: 857–87. doi: 10.1002/(sici)1097-0258(19980430)17:8<857:aid-sim777>3.0.co;2-e 14. Hou H., Wang T., Zhang B., Luo Y., Mao L., Wang F. et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin. Transl. Immunology 2020; 9(5): e01136. doi: 10.1002/cti2.1136 15. Vabret N., Britton G.J., Gruber C., Hegd S., Kim J., Kuksin M. et al. The Sinai Immunology Review Project. Immunology of COVID-19: cur-rent state of the science. Cell Press, 2020. DOI: https://doi.org/10.1016/j.immuni. 2020.05.002 16. Chang D., Mo G., Yuan X., Tao Y., Peng X., Wang F.-S. et al. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection. Am. J. Respir. Crit. Care Med. 2020; 201(9): 1150–2. doi: 10.1164/rccm.202003-0524LE 17. Kronbichler A., Kresse D., Yoon S., Lee K.H., Effenberger M., Shin J.I. Asymptomatic patients as a source of COVID-19 infections: A systematic review and metaanalysis. Int. J. Infect. Dis. 2020; 98: 180–6. doi: 10.1016/j.ijid.2020.06.052. 15 18. Popova A.Yu., Ezhlova E.B., Mel’nikova A.A., Historik O.A., Mosevich O.S., Lyalina L.V. et al. [Assessment of the Herd Immunity to SARS-CoV-2 amongthe Population of the Leningrad Region during the COVID-19 Epidemic]. Problemy osobo opasnykh infektsii (In Russ.). DOI: 10.21055/0370-1069-2020-3-114-123 19. Vlasova A.N., Zhang X., Hasoksuz M., Nagesha H.S., Haynes L.M., Y. Fang et al. Two-Way Antigenic Cross-Reactivity between Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Group 1 Animal CoVs Is Mediated through an Antigenic Site in the N-Terminal Region of the SARS-CoV Nucleoprotein. J. Virol. 2007; 81(240022): 13365–77. doi:10.1128/JVI.01169-07 20. Lynch K.L., Whitman J.D., Lacanienta N.P., Beckerdite E.W., Kastner S.A., Shy B.R. et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clin. Infect. Dis. 2020; 14: 979. doi: 10.1093/cid/ciaa979 21. Cai J., Sun W., Huang J., Gamber M., Wu J., He G. Indirect Virus Transmission in Cluster of COVID-19 Cases, Wenzhou, China, 2020. Emerg. Infect. Dis. 2020; 26(6): 1343–5. doi: 10.3201/eid2606.200412
About the Autors
Professor Anna Yu. Popova, MD; Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; depart@gsen.ru; https://orcid.org/0000-0002-4315-5307
Elena B. Ezhlova, Cand. Med. Sci., Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; ezhlova_eb@gsen.ru
Albina A. Melnikova, Cand. Med. Sci., Epidemiological Surveillance Directorate, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; melnikova_aa@gsen.ru; http://orcid.org/0000-0002-5651-1331
Elena E. Oglezneva, Directorate for the Belgorod Region, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Belgorod, Russia; orgotd@31rospotrebnadzor.ru; https://orcid.org/0000-0001-7402-9998.
Aleksandr S. Krasnoperov, Center for Hygiene and Epidemiology in the Belgorod Region, Belgorod, Russia; orgotdel@31fbuz.ru; https://orcid.org/0000-0001-7400-8011
Professor Lyudmila V. Lyalina, MD; Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Saint Petersburg, Russia; lyalina@pasteurorg.ru; http://orcid.org/0000-0001-9921-3505
Professor Vyacheslav S. Smirnov, MD; Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Saint Petersburg, Russia; vssmi@mail.ru; http://orcid.org/0000-0002-2723-1496
Andrey D. Demin, Center for Hygiene and Epidemiology in the Belgorod Region, Belgorod, Russia; demin@31fbuz.ru; https://orcid.org/0000-0003-0000-0150
Zhanna V. Kobrinets, Center for Hygiene and Epidemiology in the Belgorod Region, Belgorod, Russia; orgotdel@31fbuz.ru; https://orcid.org/0000-0001-9057-2982
Aleksandra Yu. Cherskova, Center for Hygiene and Epidemiology in the Belgorod Region, Belgorod, Russia; sgm@31fbuz.ru; https://orcid.org/0000-0001-7759-3172
Vsevolod A. Zhidkov, Center for Hygiene and Epidemiology in the Belgorod Region, Belgorod, Russia; orgotdel@31fbuz.ru; https://orcid.org/0000-0002-7325-4496
Daria A. Velitchenko, Center for Hygiene and Epidemiology in the Belgorod Region, Belgorod, Russia; orgotdel@31fbuz.ru
Valeria I. Lomonosova, Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Saint Petersburg, Russia; valeriyanagorskaya94@yandex.ru; https://orcid.org/0000-0002-4531-2724
Tatiana V. Arbuzova, Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Saint Petersburg, Russia; arbuzowa95@yandex.ru; https://orcid.org/0000-0002-3074-8656
Professor Areg A. Totolyan, Academician of the Russian Academy, Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Saint Petersburg, Russia; pasteur@pasteurorg.ru; https://orcid.org/ 0000- 0003-4571-8799
Similar Articles
